Quick Answer
Acacia Fiber Constipation Meta-Analysis has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: It is characterized by abdominal pain associated with defecation or with changes in stool frequency or consistency.
Key Takeaways
- 01It is characterized by abdominal pain associated with defecation or with changes in stool frequency or consistency. [JanssenDuijghuijsen Lonneke (2024)]
- 02Constipation in general increases the risk for diseases such as colorectal cancer, Parkinson’s disease, cardiovascular disease, and all-cause mortality [–]. [JanssenDuijghuijsen Lonneke (2024)]
- 03The daily dose of the Acacia fiber (AF) supplement (Inavea™ Pure Acacia, Nexira, Rouen, France) was gradually increased from 5 g during the first five days to 10 g during the remainder of the intervention period, to prevent increase in GI complaints due to a sudden increase in daily fiber intake. [JanssenDuijghuijsen Lonneke (2024)]
- 041 2 2 3 4 6 Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder, which affects 10–20% of the total world population, with a higher prevalence observed among women [,]. [JanssenDuijghuijsen Lonneke (2024)]
The current Migaku evidence database contains 1 reusable source document for Acacia Fiber Constipation Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove.
- It is characterized by abdominal pain associated with defecation or with changes in stool frequency or consistency. [JanssenDuijghuijsen Lonneke (2024); evidence level 2]
- Constipation in general increases the risk for diseases such as colorectal cancer, Parkinson’s disease, cardiovascular disease, and all-cause mortality [–]. [JanssenDuijghuijsen Lonneke (2024); evidence level 2]
- The daily dose of the Acacia fiber (AF) supplement (Inavea™ Pure Acacia, Nexira, Rouen, France) was gradually increased from 5 g during the first five days to 10 g during the remainder of the intervention period, to prevent increase in GI complaints due to a sudden increase in daily fiber intake. [JanssenDuijghuijsen Lonneke (2024); evidence level 2]
- 1 2 2 3 4 6 Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder, which affects 10–20% of the total world population, with a higher prevalence observed among women [,]. [JanssenDuijghuijsen Lonneke (2024); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources